Organisation paid for research Program year 2025 Source: CMS Open Payments

Washington Univ

Neither a doctor nor a teaching hospital

Research payments

$5,372,933

134 payments

Through program year 2025, Washington Univ is reported as receiving $5,372,933 in research payments, across 134 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$318,713	4
2023	Research	$2,236,174	17
2022	Research	$137,894	4
2021	Research	$540,701	43
2020	Research	$1,114,728	28
2019	Research	$1,024,722	38

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $3,689,157 30 payments
AstraZeneca Pharmaceuticals LP $674,807 42 payments
Merck Sharp & Dohme Corporation $651,451 4 payments
Siemens Medical Solutions USA, Inc. $180,060 6 payments
Acerta Pharma LLC $61,729 6 payments
GlaxoSmithKline, LLC. $45,380 10 payments
Alexion Pharmaceuticals, Inc. $27,164 1 payment
AstraZeneca AB $12,328 2 payments
Agios Pharmaceuticals, Inc. $9,477 7 payments
AstraZeneca UK Limited $8,556 4 payments

Studies the money was for Research payments · program years 2019–2025

AMG 510 Ph1b Master Protocol 20190135 $1,724,346 3 payments
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs Neoantigen Vaccine plus Durvalumab inTriple Negative Breast Cancer Patients following Standard of Care Therapy $449,630 4 payments
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. $334,093 2 payments
A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas $307,476 1 payment
CB100 Dose Comparison Study $299,606 2 payments
AMG 510 - Adv. KRAS G12C solid tumors_20190135 $252,043 1 payment
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 $248,481 1 payment
Amg 757_Sclc_20160323 $236,314 5 payments
Immunotherapy with MK-3475 in locoregionally advanced, surgically resectable head and neck squamous cell carcinoma $235,680 2 payments
AMG 701 Ph1/2 Non-Randomized Open-Label Expansion MM $180,644 1 payment

What the money was spent on Research payments · program years 2019–2025

Patient care $1,531 17 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.